Physician profile
Sandeep Garg
NPI 1316927882
$23,015.04
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $69.54 · 2021: $1,336 · 2022: $1,585 · 2023: $1,450 · 2024: $5,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,398 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,397.50 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $7,911.35 | 2019 | |
| Incyte Corporation | $5,119.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $4,560.00 | 2022-2024 | Imfinzi, Calquence |
| Daiichi Sankyo INC. | $1,328.13 | 2019-2023 | |
| Seagen INC. | $1,250.00 | 2023 | |
| Glaxosmithkline, LLC. | $825.00 | 2021 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Astellas Pharma US INC | $527.59 | 2019-2021 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Inari Medical, INC. | $187.44 | 2022 | |
| Amgen INC. | $68.47 | 2019 | |
| Pfizer INC. | $41.81 | 2019 | |
| Genentech USA, INC. | $35.60 | 2019 | |
| Janssen Biotech, INC. | $33.54 | 2019 | |
| Exelixis INC. | $33.15 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.63 | 2019-2021 | |
| Genzyme Corporation | $26.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.28 | 2020 | |
| Lilly USA, LLC | $21.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.19 | 2019 | |
| Kite Pharma, INC. | $20.15 | 2020 | |
| Gilead Sciences, INC. | $15.80 | 2019 | |
| Emd Serono, INC. | $15.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.84 | 2020 | |
| Merck Sharp & Dohme LLC | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.